Corvus Pharmaceuticals
Clinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer.
Launch date
Employees
Market cap
€290m
Enterprise valuation
€248m (Public information from Sep 2024)
Share price
$5.61 CRVS
Burlingame California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | - | 5.6m | 5.8m |
| % growth | - | - | - | - | - | - | 4 % |
| EBITDA | (43.8m) | (43.2m) | (32.6m) | (23.3m) | - | - | - |
| Profit | (6.0m) | (43.2m) | (41.3m) | (27.0m) | (24.7m) | (39.0m) | (50.1m) |
| % profit margin | - | - | - | - | - | (692 %) | (858 %) |
| EV / revenue | - | - | - | - | - | 49.7x | 48.0x |
| EV / EBITDA | -2.3x | -2.6x | -1.2x | -3.7x | - | - | - |
| R&D budget | 31.8m | 29.1m | 24.5m | 16.5m | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$33.5m | Series A | ||
| N/A | $75.0m | Series B | |
| N/A | N/A | IPO | |
* | $30.6m | Post IPO Equity | |
| Total Funding | €98.6m | ||
Related Content
Recent News about Corvus Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.